See more : CubicFarm Systems Corp. (CUB.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Bavarian Nordic A/S (BVNKF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bavarian Nordic A/S, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Environmental Solutions Worldwide, Inc. (ESWW) Income Statement Analysis – Financial Results
- Ningbo Yunsheng Co., Ltd. (600366.SS) Income Statement Analysis – Financial Results
- Unum Group (UNM) Income Statement Analysis – Financial Results
- Shenzhen KSTAR Science and Technology Co., Ltd. (002518.SZ) Income Statement Analysis – Financial Results
- Old Republic International Corporation (ORI) Income Statement Analysis – Financial Results
Bavarian Nordic A/S (BVNKF)
About Bavarian Nordic A/S
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.06B | 3.15B | 1.90B | 1.85B | 662.49M | 500.62M | 1.37B | 1.01B | 1.02B | 1.22B | 1.21B | 1.02B | 523.60M | 314.07M | 74.78M | 208.81M | 332.10M | 175.29M | 247.60M | 164.78M | 504.64M | 121.08M | 0.00 |
| Cost of Revenue | 2.46B | 1.45B | 1.33B | 1.20B | 354.76M | 255.12M | 290.62M | 297.79M | 415.14M | 495.08M | 484.71M | 513.55M | 403.39M | 444.47M | 140.10M | 196.66M | 55.12M | 110.80M | 132.23M | 70.25M | 187.19M | 56.45M | 0.00 |
| Gross Profit | 4.60B | 1.70B | 570.32M | 657.29M | 307.73M | 245.50M | 1.08B | 708.95M | 605.42M | 721.73M | 727.80M | 503.08M | 120.21M | -130.40M | -65.32M | 12.15M | 276.99M | 64.50M | 115.37M | 94.53M | 317.45M | 64.62M | 0.00 |
| Gross Profit Ratio | 65.18% | 53.99% | 30.05% | 35.48% | 46.45% | 49.04% | 78.79% | 70.42% | 59.32% | 59.31% | 60.02% | 49.49% | 22.96% | -41.52% | -87.34% | 5.82% | 83.40% | 36.79% | 46.60% | 57.37% | 62.91% | 53.37% | 0.00% |
| Research & Development | 2.35B | 1.18B | 399.16M | 341.42M | 409.28M | 386.30M | 518.41M | 463.17M | 386.81M | 478.93M | 496.61M | 357.44M | 261.72M | 210.83M | 163.98M | 129.65M | 134.96M | 39.28M | 114.38M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 419.85M | 376.02M | 292.92M | 278.15M | 173.42M | 179.96M | 168.06M | 174.21M | 174.79M | 181.02M | 156.99M | 137.76M | 133.40M | 104.58M | 91.48M | 92.04M | -1.57M | -76.37M | 75.39M | 56.42M | 42.99M | 31.40M | 21.96M |
| Selling & Marketing | 331.58M | 212.93M | 191.78M | 285.78M | 53.48M | 33.73M | 39.88M | 38.56M | 42.27M | 45.11M | 40.78M | 39.57M | 33.35M | 28.28M | 20.41M | 0.00 | 2.58M | 77.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 751.43M | 588.96M | 484.70M | 563.93M | 226.89M | 213.68M | 207.94M | 212.77M | 217.06M | 226.13M | 197.77M | 177.32M | 166.75M | 132.86M | 111.89M | 92.04M | 1.00M | 819.00K | 75.39M | 56.42M | 42.99M | 31.40M | 21.96M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -627.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 3.11B | 1.77B | 883.86M | 277.70M | 636.18M | 599.98M | 726.34M | 675.94M | 603.87M | 705.06M | 694.38M | 534.76M | 428.48M | 343.69M | 275.87M | 235.53M | 342.01M | 268.26M | 235.14M | 176.85M | 103.41M | 91.27M | 93.48M |
| Cost & Expenses | 5.01B | 3.22B | 2.21B | 1.47B | 990.93M | 855.10M | 1.02B | 973.74M | 1.02B | 1.20B | 1.18B | 1.05B | 831.87M | 788.16M | 415.97M | 432.19M | 397.13M | 379.06M | 367.37M | 247.10M | 290.60M | 147.73M | 93.48M |
| Interest Income | 40.21M | 26.00K | 1.74M | 193.00K | 602.00K | 842.00K | 644.00K | 272.00K | 38.00K | 12.00K | 29.00K | 667.00K | 21.65M | 4.19M | 7.76M | 40.09M | 25.71M | 4.36M | 19.67M | 9.77M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 105.52M | 119.69M | 152.06M | 177.00M | 18.49M | 14.53M | 5.68M | 7.06M | 6.53M | 6.28M | 6.49M | 7.96M | 9.76M | 13.54M | 17.81M | 40.09M | 2.13M | 2.27M | 16.32M | 4.17M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 553.82M | 399.25M | 387.69M | 344.08M | 57.05M | 41.64M | 106.81M | 44.08M | 43.53M | 44.95M | 46.22M | 56.45M | 53.88M | 49.74M | 49.23M | 48.34M | 40.14M | 17.95M | 15.39M | 0.00 | 12.93K | 5.13M | 3.60M |
| EBITDA | 2.14B | 395.40M | 85.94M | 819.13M | -269.21M | -300.47M | 345.09M | 91.98M | 127.69M | 115.58M | 58.92M | 10.54M | -234.24M | -420.16M | -273.23M | -175.05M | -36.06M | -184.58M | -84.71M | -82.32M | 214.05M | -21.52M | -89.88M |
| EBITDA Ratio | 30.33% | 12.55% | 6.59% | 43.72% | -39.15% | -55.51% | 25.19% | 11.20% | 12.45% | 5.40% | 5.28% | 2.69% | -44.45% | -133.78% | -353.15% | -83.83% | -2.48% | -105.30% | -34.21% | -49.96% | 42.42% | -17.77% | 0.00% |
| Operating Income | 1.50B | -3.85M | -263.31M | 449.62M | -316.43M | -319.51M | 307.56M | 67.34M | 83.51M | 20.72M | 17.84M | -29.08M | -286.62M | -469.90M | -313.32M | -223.39M | -48.36M | -202.53M | -100.10M | -82.32M | 214.04M | -26.65M | -93.48M |
| Operating Income Ratio | 21.28% | -0.12% | -13.87% | 24.27% | -47.76% | -63.82% | 22.45% | 6.69% | 8.18% | 1.70% | 1.47% | -2.86% | -54.74% | -149.61% | -418.98% | -106.98% | -14.56% | -115.54% | -40.43% | -49.96% | 42.41% | -22.01% | 0.00% |
| Total Other Income/Expenses | -19.60M | -260.83M | -191.12M | -97.61M | -16.30M | -2.15M | -50.91M | 6.54M | 76.08M | 47.69M | 78.04M | -17.04M | 11.88M | -9.35M | 10.05M | 26.25M | -2.13M | -2.27M | -16.32M | 5.60M | 3.59M | 936.00K | 2.54M |
| Income Before Tax | 1.48B | -331.61M | -454.43M | 281.98M | -344.75M | -356.64M | 302.28M | 39.55M | 77.63M | 64.36M | 6.20M | -48.73M | -296.38M | -483.44M | -331.13M | -183.30M | -50.49M | -204.79M | -116.42M | -76.72M | 217.63M | -25.71M | -90.94M |
| Income Before Tax Ratio | 21.00% | -10.52% | -23.94% | 15.22% | -52.04% | -71.24% | 22.06% | 3.93% | 7.61% | 5.29% | 0.51% | -4.79% | -56.60% | -153.93% | -442.79% | -87.78% | -15.20% | -116.83% | -47.02% | -46.56% | 43.13% | -21.24% | 0.00% |
| Income Tax Expense | 7.75M | 15.77M | 10.35M | 4.46M | 2.03M | 5.29M | 120.94M | 8.95M | 18.20M | 38.42M | 52.93M | 191.28M | 27.96M | 93.53M | 64.86M | 32.94M | 13.01M | -43.86M | -21.69M | -23.71M | 67.06M | -95.83M | 1.14M |
| Net Income | 1.48B | -347.38M | -464.78M | 277.52M | -346.78M | -361.93M | 181.34M | 30.60M | 59.43M | 25.94M | -46.73M | -240.00M | -268.42M | -389.91M | -266.28M | -150.36M | -59.97M | -158.04M | -94.73M | -53.01M | 150.57M | 70.12M | -92.09M |
| Net Income Ratio | 20.89% | -11.03% | -24.49% | 14.98% | -52.34% | -72.30% | 13.24% | 3.04% | 5.82% | 2.13% | -3.85% | -23.61% | -51.26% | -124.15% | -356.07% | -72.01% | -18.06% | -90.16% | -38.26% | -32.17% | 29.84% | 57.91% | 0.00% |
| EPS | 19.20 | -4.93 | -7.37 | 5.13 | -8.50 | -8.88 | 4.54 | 0.80 | 1.69 | 0.78 | -1.42 | -7.28 | -10.24 | -26.50 | -20.89 | -9.94 | -4.14 | -12.38 | -8.65 | -5.64 | 15.02 | 7.91 | -13.55 |
| EPS Diluted | 19.23 | -4.93 | -7.37 | 5.13 | -8.50 | -8.88 | 4.50 | 0.80 | 1.64 | 0.76 | -1.42 | -7.28 | -10.24 | -26.50 | -20.89 | -9.94 | -4.14 | -12.38 | -8.65 | -5.64 | 15.02 | 7.91 | -13.51 |
| Weighted Avg Shares Out | 76.83M | 70.42M | 63.10M | 54.05M | 40.81M | 40.77M | 39.98M | 38.04M | 35.14M | 33.32M | 32.99M | 32.99M | 26.21M | 14.71M | 12.75M | 15.13M | 14.47M | 12.77M | 10.95M | 9.40M | 10.02M | 8.87M | 6.79M |
| Weighted Avg Shares Out (Dil) | 76.71M | 70.42M | 63.10M | 54.05M | 40.81M | 40.77M | 40.30M | 38.34M | 36.16M | 33.93M | 32.99M | 32.99M | 26.21M | 14.71M | 12.75M | 15.13M | 14.47M | 12.77M | 10.95M | 9.40M | 10.02M | 8.87M | 6.82M |
Mpox vaccine maker Bavarian Nordic's stock jumps 10% as European country places jumbo order for doses
Bavarian Nordic's stock soared 10% on Thursday after the Danish biotech company posted better-than-expected second-quarter earnings and unveiled an order for 440,000 doses of smallpox and mpox vaccines from an undisclosed European country.
Bavarian Nordic Stock Jumps on Revenue Beat, Mpox Vaccine Order
Shares of Bavarian Nordic are surging 12% in Danish trading after the company with the only approved mpox vaccine in the U.S. and Europe posted a quarterly revenue beat and announced a huge vaccine order.
Mpox Vaccine Maker Bavarian Nordic Shares Soar Amid Concern Over Virus Outbreak
Shares of Danish biotech Bavarian Nordic surged on Thursday after the company reported strong earnings and a large order of its mpox vaccine, extending its gains this year as nations mobilize to combat an escalating outbreak of the disease in...
Bavarian Nordic shares pop over 12% on earnings beat, bumper mpox vaccine order
Shares of Danish biotech company Bavarian Nordic jumped in early deals Thursday after reporting first-half earnings and a bumper mpox vaccine order.
Bavarian Nordic Receives 440,000 Dose Contract to Supply Smallpox and Mpox Vaccines for Undisclosed European Country
COPENHAGEN, Denmark, August 21, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a contract of 440,000 doses to supply its MVA-BN® smallpox/mpox vaccine to an undisclosed European country.
Bavarian Nordic will decide this week on mpox vaccine ramp up, CEO says
Danish biotech firm Bavarian Nordic is considering ramping up production of its mpox vaccine without having orders lined up, based on talks this week with the World Health Organisation, the company's CEO told Reuters on Tuesday.
Bavarian Nordic: Jynneos Expansion Amid Global Health Emergencies
Bavarian Nordic specializes in vaccines for infectious diseases and immuno-oncology therapies, with Jynneos being a featured vaccine. Jynneos, Bavarian's vaccine for smallpox and monkeypox, is the only FDA-approved option for both conditions. Bavarian Nordic's 2024 revenue guidance is between $710...
Bavarian Nordic to ramp up production of mpox vaccine
Danish biotech firm Bavarian Nordic said on Saturday it plans to ramp up production of its mpox vaccine and is working closely with all stakeholders to ensure fair access to the vaccine as mpox has been declared a global public...
Bavarian Nordic shares up 45% this week on mpox outbreak
Biotech firm Bavarian Nordic shares soared over 15% on Friday, another day of substantial gains which analysts have linked to the outbreak of the mpox virus.
Mpox vaccine maker Bavarian Nordic seeks ‘critical' EU approval for teens after WHO declares health emergency
Danish biotech company Bavarian Nordic said Friday that it had submitted data to the Europe Union's drug regulator to extend the use of its mpox vaccine for teenagers. CEO Paul Chaplin told CNBC that the expanded approval for 12 to...
Source: https://incomestatements.info
Category: Stock Reports